KLRK1 and neoplasm: Cancer therapies targeting activating NKG2D, a major activating receptor for NK cells, has been shown to improve NK cell responses leading to the suppression of tumor growth and the reduced formation of metastases in various tumor types, such as melanoma, osteosarcoma and hepatocellular carcinoma (49).